Lundbeck is committed to providing information that may help patients and providers throughout the access and reimbursement process. Below are resources that may be helpful. Resources and access support are also available from a VYEPTI CONNECT Liaison or a Field Reimbursement Specialist.

Downloadable resources

Downloadable VYEPTI resource

VYEPTI CONNECT Enrollment Form

Download the enrollment form and begin the benefits investigation process.

Downloadable VYEPTI resource

VYEPTI CONNECT Overview

Download information about VYEPTI CONNECT. This optional program for patients and providers offers access support throughout the treatment journey.

Downloadable VYEPTI resource

Physician Attestation

Physicians who do not wish to enroll in VYEPTI CONNECT but still want access and reimbursement support from a Field Reimbursement Specialist should download and submit this form.

Downloadable VYEPTI resource

California Patient Attestation

Providers in California who have prescribed VYEPTI must have their patients fill out this form and submit it along with the VYEPTI CONNECT Enrollment Form.

Downloadable VYEPTI resource]

How to Order VYEPTI Under the Medical Benefit

Information about the ordering and distribution of VYEPTI under the medical benefit.

Downloadable VYEPTI resource

Billing and Coding Guide

Information that may be helpful when submitting claims for VYEPTI.

Downloadable VYEPTI resource

Prior Authorization (PA) Checklist

Information that can help you organize material that may be needed to complete a PA for VYEPTI.

Downloadable VYEPTI resource

Sample Letter of Medical Necessity

Information about what may be needed to complete a Letter of Medical Necessity.

Downloadable VYEPTI resource

Sample Letter of Appeal

Information about what may be needed to complete a Letter of Appeal.

Downloadable VYEPTI resource

VYEPTI Copay Assistance Program

Information on eligibility requirements and how your commercial patients can enroll in the program.

Downloadable VYEPTI resource

VYEPTI CONNECT Terms and Conditions

Review the Terms and Conditions for VYEPTI CONNECT support.

Downloadable VYEPTI resource

VYEPTI Copay Assistance Program Terms and Conditions

Review the Terms and Conditions for the VYEPTI Copay Assistance Program.

Want to hear when more resources become available?

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.